SynthesisAnnals of surgical oncology2026

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis.

Guilherme Franceschini Machado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.